Results established unprecedented traction in rare kidney disease trial recruitment.
Prepare for the changing world of audience targeting by requesting our exclusive POV
2018 was a ground-breaking year for orphan disease with the FDA approving a record 34 new therapies for rare populations. Clearly, the steps laid out
Pharma marketers experienced both flops and wins in 2018 – here’s how to apply these learnings to drive impact in the new year.